Bsf Enterprise Plc · LSE:BSFA

Bsf Enterprise — Investor Presentation (October 2024)

21 slides from Bsf Enterprise's investor presentation, October 2024

1. Slide 1: Unlocking the next generation of tissue engineered materials

   LON: BSFA (UK) | BSFAF: QB (US) Unlocking the next generation of tissue engineered materials INVESTOR PRESENTATION October 2024 1 © 2024 BSF Enterprise PLC. All rights reserved.

2. Slide 2: Executive Summary

   LON: BSFA (UK) | BSFAF: QB (US) Executive Summary • BSF Enterprise PLC develops cutting-edge biotechnological solutions for sustainable tissue engineered materials, including lab-grown leather, cultivated meat and human corneas. • Differentiated superior tissue engineering platform to create “scaffold

3. Slide 3: BSF Enterprise PLC – Management Team

   LON: BSFA (UK) | BSFAF: QB (US) BSF Enterprise PLC – Management Team Dr. Che Connon Geoffrey Baker Min Yang Managing Director Executive Director Executive Director o Internationally o A qualified lawyer in o A wealth of experience acknowledged as a Australia and Hong spanning over 30 years leader in

4. Slide 4: BSF Enterprise PLC – Management Team (continued)

   LON: BSFA (UK) | BSFAF: QB (US) BSF Enterprise PLC – Management Team (continued). Graham Duncan Ricardo Gouveia Marcelo Bravo CFO CSO CBO o A Chartered o Scientist with expertise o Seasoned entrepreneur Accountant with over in biochemistry, and C-level executive 20 years of capital biotechnology, an

5. Slide 5: Biotech that addresses real challenges

   Biotech that addresses real challenges. • Livestock farming causes 24% of greenhouse gas emissions, uses 33% of drinking water, and 66% of antibiotics. • It leads to more deforestation than soy, palm oil, and wood combined. • Tissue engineered cultured alternatives can eliminate the slaughter of 70

6. Slide 6: What’s Scaffold-Free?

   What’s Scaffold-Free? • Tissues need structure and cells for proper texture, strength, and mouthfeel. • Tissue engineered materials often use synthetic or plant-based scaffolds for structure which affect the natural feel and quality of the final product. • Our patented process lets cells create their o

7. Slide 7: Multiple Growth Opportunities

   LON: BSFA (UK) | BSFAF: QB (US) Multiple Growth Opportunities 3D Bio-Tissues Cultivated Meat Lab-Grown Technologies Leather 7 © 2024 BSF Enterprise PLC. All rights reserved.

8. Slide 8: Lab-Grown Leather Ltd

   LON: BSFA (UK) | BSFAF: QB (US) Lab-Grown Leather Ltd In 2023, 3DBT engineered samples of animal skin tissue. BSF is initiating development programmes with three of the five most valuable global luxury brands. Now developing a separate business – Lab-Grown Leather – to scale up technical development

9. Slide 9: Case Study: 3DBT Skin

   LON: BSFA (UK) | BSFAF: QB (US) Case Study: 3DBT Skin Real Leather Without The Animal We are the only company in the world able to make real leather without additives (‘scaffolds’) 9 © 2024 BSF Enterprise PLC. All rights reserved.

10. Slide 10: Making Headlines

    LON: BSFA (UK) | BSFAF: QB (US) Making Headlines 10 © 2024 BSF Enterprise PLC. All rights reserved.

11. Slide 11: The Process

    LON: BSFA (UK) | BSFAF: QB (US) The Process Cell Culture Tanning, Post-tanning & Finishing Cultivated Skin (3DBT Skin) Animal Cell Isolation Lab-Grown Leather 11 © 2024 BSF Enterprise PLC. All rights reserved.

12. Slide 12: Significant potential to transform the leather goods market

    LON: BSFA (UK) | BSFAF: QB (US) Significant potential to transform the leather goods market Adding a sustainable choice to traditional leather, without compromising on quality, luxury, or environmental integrity. • Bio-based leather alternatives, reaching >$2B by 2030 • 3DBT Skin uniquely replicates

13. Slide 13: Kerato Ltd

    LON: BSFA (UK) | BSFAF: QB (US) Kerato Ltd • Kerato leverages advances in tissue engineering to address the global shortage of donor human corneas for Protein Chicken Beef Pork medical and research uses. • Developing LiQD Cornea, a novel Impact on alternative for corneal repair, reducing global warm

14. Slide 14: Cultivated Meat Technologies Ltd

    LON: BSFA (UK) | BSFAF: QB (US) Cultivated Meat Technologies Ltd • 3DBT’S R&D has generated leading IP in the growth of cells and production of cultivated meat with class-leading sensory attributes • CMT uses expertise with 3DBT’s tissue engineering technology and City-Mix™ media supplements to driv

15. Slide 15: BSF Enterprise (Hong Kong) Ltd

    LON: BSFA (UK) | BSFAF: QB (US) BSF Enterprise (Hong Kong) Ltd • Established presence in Hong Kong to Protein Chicken Beef Pork bring the companies tissue engineered materials to the Greater China market. • China consumes over 100 million tons Impact on of meat annually, a quarter of global global w

16. Slide 16: Next 18 Months: Multiple Value Inflection Points

    LON: BSFA (UK) | BSFAF: QB (US) Next 18 Months: Multiple Value Inflection Points • Kerato: Completion of veterinary clinical trials and commercial launch of corneal repair technology. • 3DBT: Increase supply of City-Mix ™ to leading cultivated meat partner and launch of CytoBoost ™ range to Research

17. Slide 17: Appendix

    Appendix LON:BSFA (UK) BSFAF:QB (US) www.bsfenterprise.com © 2024 BSF Enterprise PLC. All rights reserved. 17 © 2024 BSF Enterprise PLC. All rights reserved.

18. Slide 18: Investor Relations Information

    Investor Relations Information Shareholders % Holdings Advisors BSF Angel Funding LTD 16.08 Brokerage Che Connon 12.50* Shard Capital Brokers Jarvis Inv Mgmt Ltd 12.09 UK Legal Hargreaves Lansdown plc 9.47 Reynolds Porter Chamberlain LLP Newcastle University Holdings Ltd 6.70 Communications Interact

19. Slide 19: Presentation Disclaimer

    Presentation Disclaimer. The information contained in these slides and communicated orally to you, including the speech(es) of the presenter(s) and any materials distributed at or in connection therewith (together, the “Presentation”) is confidential. By reading the information contained in this Pre

20. Slide 20: Presentation Disclaimer (continued)

    Presentation Disclaimer (continued). The Presentation has not been approved by the FCA and does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or

21. Slide 21: www.bsfenterprise.com

    LON:BSFA (UK) BSFAF:QB (US) www.bsfenterprise.com 21 © 2024 BSF Enterprise PLC. All rights reserved.

BSF Enterprise — Investor Presentation (October 2024) on 6ix